A randomised trial in 147 adults aged 60 to 85 tested two infusions of umbilical cord mesenchymal stem cells (UC-MSCs) in age-related frailty. After nine months, there were no serious adverse events linked to the therapy, and physical performance was better in the treated group than in controls.
Age-related frailty is more than getting older
Age-related frailty is a clinical syndrome, not a synonym for old age. It describes reduced physiological reserve across several body systems at once.
The result is disproportionate vulnerability: an event a robust person would shrug off, such as a fall, flu or a short hospital stay, can trigger a loss of independence that is hard to reverse.
How it is identified
Geriatricians most often use the Fried criteria, which look at five signs: unintentional weight loss, persistent exhaustion, weak handgrip, slow walking speed and low physical activity. Three or more define frailty. It independently predicts hospital admission, disability and death, which makes it a research priority as populations age.
The study: 147 participants, two infusions, nine months
The trial ran from 2021 to 2024 at Vinmec Times City International Hospital in Hanoi, Vietnam, and was published in 2026 in eBioMedicine, part of The Lancet group.
- Participants: 147 adults aged 60 to 85 meeting at least three modified Fried criteria.
- Treated group: two intravenous UC-MSC infusions (1.5 million cells per kg), three months apart, plus oral supplements.
- Control group: oral supplements only.
- Follow-up: nine months.
- Design: phase 2, randomised, controlled, open-label, single-centre.
Safety
No serious adverse events related to the therapy occurred. Twelve mild events, including headache, dizziness and chest discomfort, resolved on their own.
Age-related frailty and cord stem cells: functional results
The main outcome was the Short Physical Performance Battery (SPPB), which scores balance, walking speed and rising from a chair on a 0 to 12 scale.
At nine months, the treated group scored on average 1.1 points higher than controls (95% CI 0.6–1.6). In geriatrics, a difference of about one SPPB point is generally regarded as clinically meaningful.
The authors also report improvements in:
- handgrip strength, one of the most reliable markers of muscle health;
- fatigue, with lower levels and more participation in daily activity;
- self-rated quality of life, measured with the SF-36.
These are not laboratory values but measures of function: what a person can actually do, such as walking, standing up or carrying shopping.
Possible mechanisms: inflammation, senescence, mitochondria
The study also explored how UC-MSCs might work, pointing to anti-inflammatory and immunomodulatory effects. The authors describe lower markers of chronic inflammation, notably IL-6 and TNF-α, typical of inflammaging; lower markers of cellular senescence; and signs of better mitochondrial function, a key factor in sarcopenia.
How to read these results
With caution. A phase 2 trial looks for an efficacy signal and a first safety profile; it cannot prove a definitive clinical benefit. Three further limits apply:
- Open-label design: participants knew their group, which matters for subjective outcomes such as fatigue and quality of life.
- No placebo: controls did not receive a sham infusion, only supplements.
- Single centre: results need confirming in other populations and settings.
The authors call for larger, multicentre, double-blind phase 3 trials, including to define optimal doses and intervals.
Important note. The applications described belong to clinical research and are not approved therapies. Nothing in this article constitutes medical advice, and it does not promote anti-ageing treatments.
Why SSCB follows research on cord tissue stem cells
The trial used mesenchymal stem cells derived from umbilical cord tissue. This source differs from cord blood: it is rich in mesenchymal cells, the type studied for their anti-inflammatory and immunomodulatory action.
SSCB, the only Swiss biobank accredited by FACT-NetCord, preserves cord tissue alongside cord blood and placenta. Different sources contain different cell populations, and studies like this one show how wide the field of research on them has become: from birth to later life.
Umbilical cord mesenchymal stem cells are also the focus of our article on a real-world study of 120 patients.
Want to know what umbilical cord tissue contains? Discover umbilical cord stem cells.
Frequently asked questions on age-related frailty and cord stem cells
What is age-related frailty? A clinical syndrome of reduced physiological reserve across several organs and systems, which makes older people more vulnerable to falls, infections and hospital admission.
Are umbilical cord stem cells an approved treatment for frailty? No. The available studies, including this one, are clinical research. Phase 3 trials are needed to confirm efficacy and safety.
What does the SPPB test measure? Balance, walking speed and the ability to rise from a chair, scored from 0 to 12.
Source: Nguyen LT, et al. Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial. eBioMedicine. 2026;127:106268.
